US2022228122A1PendingUtilityA1

Methods of isolation and use of cd39 stromal stem cells

Assignee: ORBSEN THERAPEUTICS LTDPriority: Jul 14, 2017Filed: Jan 28, 2022Published: Jul 21, 2022
Est. expiryJul 14, 2037(~11 yrs left)· nominal 20-yr term from priority
Y02A50/30A61K 9/06C12N 5/0663A61P 1/16A61P 11/00A61P 19/02A61K 35/28C12N 5/0605A61K 9/0019A61P 29/00A61P 13/12A61P 17/02C12N 5/0662A61P 37/06A61K 9/0014C12N 5/0668A61K 35/35A61P 25/28G01N 33/54313
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are methods of isolating SDC2+ stromal stem cells and exosomes from SDC2+ stromal stem cells by expression of surface marker CD39. Also disclosed herein are stromal stem cells and exosomes isolated by said methods.

Claims

exact text as granted — not AI-modified
1 .- 11 . (canceled) 
     
     
         12 . A method of modulating an inflammation response in a mammal comprising delivering a composition comprising SDC2+ cells to a site of the inflammation response, wherein the SDC2+ cells are isolated from a mixed population of cells by isolating cells based upon CD39 expression. 
     
     
         13 . The method of  claim 12 , wherein isolating cells comprises collecting cells bound to a CD39 binding agent. 
     
     
         14 . The method of  claim 13 , wherein isolating the cells comprises culturing the cells bound to the CD39 binding agent. 
     
     
         15 . The method of  claim 12 , wherein delivering comprises injecting the composition comprising SDC2+ cells. 
     
     
         16 . The method of  claim 12 , wherein delivering comprises topically applying the composition comprising SDC2+ cells. 
     
     
         17 . The method of  claim 16 , wherein the composition comprises a hydrogel. 
     
     
         18 . The method of  claim 16 , wherein the composition comprises a collagen gel. 
     
     
         19 . The method of  claim 12 , wherein delivering comprises intravenous delivery the composition comprising SDC2+ cells. 
     
     
         20 . The method of  claim 12 , wherein the CD39 binding agent comprises an antibody. 
     
     
         21 . The method of  claim 20 , wherein the antibody is conjugated to a fluorophore. 
     
     
         22 . The method of  claim 20 , wherein the antibody is conjugated to a bead. 
     
     
         23 . The method of  claim 12 , wherein at least 20% of the SDC2+ cells are SDC2+. 
     
     
         24 . The method of  claim 12 , wherein at least 40% of the SDC2+ cells are SDC2+. 
     
     
         25 . The method of  claim 12 , wherein at least 70% of the SDC2+ cells are SDC2+. 
     
     
         26 . The method of  claim 12 , wherein the method comprises delivering at least 10{circumflex over ( )}3 SDC2+ cells. 
     
     
         27 . The method of  claim 12 , wherein the inflammation response comprises at least one of type 1 diabetes, type 2 diabetes, sepsis, Crohn's disease, inflammatory bowel syndrome, rheumatoid arthritis, graft versus host disease, multiple sclerosis, ALS, a dermal wound, a bone fracture, a concussion wound, a burn, atherosclerosis, nephropathy, cardiomyopathy, neuropathy, a kidney disorder, kidney failure, a diabetic ulcer, a leg ulcer, ARDS, sepsis, inflammatory liver disease, myocarditis, postmyocardial infarction syndrome, postpericardiotomy syndrome, subacute bacterial endocarditis, anti-glomulerular basement membrane nephritis, interstitial cystitis, lupus enphritis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, antisynthetase syndrome, asthma, chronic obstructive pulmonary disease, cystic fibrosis, atelectasis, bronchitis, emphasema, pneumonia, pulmonary endema, Alopecia Areata, autoimmune Angioedema, autoimmune progesterone dermatitis, autoimmune urticaria, Bullous pemphigoid, Cicatricial pemphigoid, Dermatitis herpetiformis, Discoid lupus erythematosus, Epidermolysis bullosa acquisita, Erythema nodosum, Gestational pemphigoid, Hidradenitis suppurativa, Lichen planus, Lichen sclerosus, Linear IgA disease, Morphea, Pemphigus vulgaris, Pityriasis lichenoides et varioliformis acuta, Mucha-Habermann disease, Psoriasis, Systemic scleroderma, Vitiligo, Addison's disease, autoimmune polyendocrine syndrome, autoimmune polyendocrine syndrome type 2, autoimmune polyendocrine syndrome type 3, autoimmune pancreatitis, autoimmune thyroiditis, Ord's thyroiditis, Graves' disease, Reproductive Organ disorder, autoimmune oophoritis, Endometriosis, autoimmune orchitis, Sjogren's syndrome, autoimmune enteropathy, Celiac disease, Microscopic colitis, Ulcerative colitis, Antiphospholipid syndrome, Aplastic anemia, autoimmune hemolytic anemia, autoimmune lymphoproliferative syndrome, autoimmune neutropenia, autoimmune thrombocytopenic purpura, Cold agglutinin disease, Essential mixed cryoglobulinemia, Evans syndrome, IgG4-related systemic disease, Paroxysmal nocturnal hemoglobinuria, Pernicious anemia, Pure red cell aplasia, Thrombocytopenia, Adiposis dolorosa, Adult-onset Still's disease, Ankylosing Spondylitis, CREST syndrome, Drug-induced lupus, Enthesitis-related arthritis, Eosinophilic fasciitis, Felty syndrome, Juvenile Arthritis, Lyme disease (Chronic), Mixed connective tissue disease, Palindromic rheumatism, Parry Romberg syndrome, Parsonage-Turner syndrome, Psoriatic arthritis, Reactive arthritis, Relapsing polychondritis, Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schnitzler syndrome, Systemic Lupus Erythematosus, Undifferentiated connective tissue disease, cachexia, sarcophenia, Dermatomyositis, Fibromyalgia, Inclusion body myositis, Myositis, Myasthenia gravis, Neuromyotonia, Paraneoplastic cerebellar degeneration, Polymyositis, Acute disseminated encephalomyelitis, Acute motor axonal neuropathy, Anti-N-Methyl-D-Aspartate Receptor Encephalitis, Balo concentric sclerosis, Bickerstaffs encephalitis, Chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, Hashimoto's encephalopathy, Idiopathic inflammatory demyelinating diseases, Lambert-Eaton myasthenic syndrome, Multiple sclerosis, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus, Progressive inflammatory neuropathy, Restless leg syndrome, Stiff person syndrome, Sydenham chorea, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, Transverse myelitis, autoimmune retinopathy, autoimmune uveitis, Cogan syndrome, Graves ophthalopathy, Intermediate uveitis, Ligneous conjunctivitis, Mooren's ulcer, Neuromyelitis optica, Opsoclonus myoclonus syndrome, Optic neuritis, Scleritis, Susac's syndrome, Sympathetic ophthalmia, Tolosa-Hunt syndrome, autoimmune inner ear disease, Meniere's disease, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Behçet's disease, Churg-Strauss syndrome, Giant cell arteritis, Henoch-Schonlein purpura, Kawasaki's disease, Leukocytoclastic vasculitis, Lupus vasculitis, Rheumatoid vasculitis, Microscopic polyangiitis, Polyarteritis nodosa, Polymyalgia rheumatica, Urticarial vasculitis, and Vasculitis. 
     
     
         28 .- 30 . (canceled)

Join the waitlist — get patent alerts

Track US2022228122A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.